Insights - Threshold Pharmaceuticals (THLD) on Friday announced early data from the Phase 1 portion of an investigator-sponsored Phase 1/2 trial of its investigational hypoxia-targeted drug TH-302 … Continue Reading
Read nowInsights - Forest Laboratories Inc. (FRX) and Gedeon Richter Plc. announced that the U.S. Federal Drug Administration (FDA) issued a complete response letter regarding the New Drug … Continue Reading
Read nowInsights - Amgen’s (AMGN) PCSK9 inhibitor evolucumab (AMG145), when added to standard treatments, helped 86% of patients get their LDL cholesterol levels to a target of 100 … Continue Reading
Read nowResearch - 2013 has been a year of change in the landscape for publicly traded antibiotic developers, driven by Cubist Pharmaceuticals’ (CBST) high-profile acquisitions of competitors Trius … Continue Reading
Read nowInsights - NPS Pharmaceuticals (NPSP) shares traded down 14% on Wednesday, despite reporting strong third quarter results and raising guidance for 2013. The weakness appears to stem … Continue Reading
Read nowResearch - Update: On November 11, Viropharma was purchased by Shire Pharma for $4.2B. The acquisition netted PropThink readers who bought alongside us saw a 100% return … Continue Reading
Read nowLong Ideas - Biogen Idec (BIIB) on Monday reported third quarter revenue of $1.8 billion, an increase of 32% from last year’s third quarter, and earnings of $2.05 … Continue Reading
Read now
